公开(公告)号：US20240261400A1

公开(公告)日：2024-08-08

申请号：US18407331

申请日：2024-01-08

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Robert C. Pordy ,  Garen Manvelian

IPC分类号： A61K39/395 ,  A61K31/397 ,  A61K31/455 ,  A61K35/413 ,  A61K39/00 ,  A61M1/34 ,  C07K16/40

CPC分类号： A61K39/3955 ,  A61K31/397 ,  A61K31/455 ,  A61K35/413 ,  A61K39/395 ,  A61M1/3496 ,  C07K16/40 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61M1/34 ,  A61M2205/33 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76

摘要： The present invention provides methods for reducing or eliminating a patient's need for lipoprotein apheresis therapy. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody. The methods of the present invention are useful for treating patients with hyperlipidemia and related conditions who are currently being treated with a therapeutic regimen comprising lipoprotein apheresis (e.g., LDL apheresis or Lp(a) apheresis).

公开(公告)号：US20240254075A1

公开(公告)日：2024-08-01

申请号：US18558726

申请日：2022-05-06

申请人： Autobahn Therapeutics, Inc.

发明人： Brian Andrew STEARNS ,  Jill Melissa BACCEI ,  Jason Randall HARRIS

IPC分类号： C07C235/20 ,  A61K31/16 ,  A61K31/165 ,  A61K31/397 ,  A61K31/40 ,  A61K31/42 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/455 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5375 ,  A61P25/00 ,  C07C235/16 ,  C07C235/22 ,  C07C235/24 ,  C07C243/28 ,  C07C255/29 ,  C07C259/06 ,  C07C313/02 ,  C07C317/28 ,  C07D205/04 ,  C07D213/75 ,  C07D237/20 ,  C07D237/22 ,  C07D239/42 ,  C07D241/20 ,  C07D261/14 ,  C07D295/18 ,  C07D305/08

CPC分类号： C07C235/20 ,  A61K31/16 ,  A61K31/165 ,  A61K31/397 ,  A61K31/40 ,  A61K31/42 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/455 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5375 ,  A61P25/00 ,  C07C235/16 ,  C07C235/22 ,  C07C235/24 ,  C07C243/28 ,  C07C255/29 ,  C07C259/06 ,  C07C313/02 ,  C07C317/28 ,  C07D205/04 ,  C07D213/75 ,  C07D237/20 ,  C07D237/22 ,  C07D239/42 ,  C07D241/20 ,  C07D261/14 ,  C07D295/18 ,  C07D305/08 ,  C07C2601/02 ,  C07C2601/14

摘要： Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restricted FAAH inhibitor.

公开(公告)号：US12042496B2

公开(公告)日：2024-07-23

申请号：US17286187

申请日：2019-10-15

申请人： University of FLorida Research Foundation, Incorporated

发明人： Kirill Martemyanov ,  Brock Grill

IPC分类号： A61K31/519 ,  A61K31/095 ,  A61K31/166 ,  A61K31/175 ,  A61K31/397 ,  A61P25/36

CPC分类号： A61K31/519 ,  A61K31/095 ,  A61K31/166 ,  A61K31/175 ,  A61K31/397 ,  A61P25/36

摘要： The present invention provides methods for modulating opioid receptor mediated analgesic effect, e.g., promoting or enhancing analgesia in subjects in need of pain relief. Also provided in the invention are methods for ameliorating or suppressing withdrawal symptoms in subjects with chronic opioid use. These methods of the invention entail administering to the subjects in need of treatment a therapeutically effective amount of a GPR139 antagonist compound. The invention further provides methods for identifying novel compounds that can be useful for modulating opioid receptor mediated analgesic effect.

公开(公告)号：US20240197666A1

公开(公告)日：2024-06-20

申请号：US18283787

申请日：2022-03-23

申请人： K-Gen Therapeutics, Inc.

发明人： Chun Jiang ,  Ruihong CHEN

IPC分类号： A61K31/22 ,  A61K31/122 ,  A61K31/222 ,  A61K31/223 ,  A61K31/23 ,  A61K31/232 ,  A61K31/336 ,  A61K31/397 ,  A61K31/405 ,  A61K31/415 ,  A61K31/421 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4409 ,  A61K39/395 ,  A61K45/06 ,  A61P17/02 ,  A61P35/00 ,  A61K39/00

CPC分类号： A61K31/22 ,  A61K31/122 ,  A61K31/222 ,  A61K31/223 ,  A61K31/23 ,  A61K31/232 ,  A61K31/336 ,  A61K31/397 ,  A61K31/405 ,  A61K31/415 ,  A61K31/421 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4409 ,  A61K39/3955 ,  A61K45/06 ,  A61P17/02 ,  A61P35/00 ,  A61K2039/505

摘要： This present disclosure relates to a method of stimulating an immune response using compounds that activate protein kinase C (PKC), including for treatment of a cancer, a precancerous lesion, a benign tumor, or a wound.

公开(公告)号：US20240190888A1

公开(公告)日：2024-06-13

申请号：US18283271

申请日：2022-03-28

申请人： SHUJING BIOPHARMA CO., LTD ,  JIANGSU NHWA PHARMACEUTICAL CO., LTD

发明人： Jun QIN ,  Yongqi WU ,  Jiaquan FENG ,  Wei HUANG ,  Yuanhai ZOU ,  Bingcheng ZHOU ,  Zhijing HU ,  Xinjian JIANG ,  Zehong WAN

IPC分类号： C07D495/04 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/407 ,  A61K31/426 ,  A61K31/429 ,  C07D333/78 ,  C07D495/20 ,  C07D513/04 ,  C07D513/20

CPC分类号： C07D495/04 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/407 ,  A61K31/426 ,  A61K31/429 ,  C07D333/78 ,  C07D495/20 ,  C07D513/04 ,  C07D513/20

摘要： Provided are a spiro-containing derivative, and a preparation method therefor and the use thereof. In particular, provided are a compound as shown in general formula (I), and a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug for preventing and/or treating central nervous system diseases related to 5-hydroxytryptamine receptors and/or trace amine-related receptors and/or dopamine receptors in mammals.

公开(公告)号：US20240189311A1

公开(公告)日：2024-06-13

申请号：US18277851

申请日：2022-02-18

申请人： NEWAMSTERDAM PHARMA B.V.

发明人： Johannes Jacob Pieter Kastelein ,  Marc Ditmarsch ,  Michael Harvey Davidson

IPC分类号： A61K31/506 ,  A61K31/397 ,  A61P3/06

CPC分类号： A61K31/506 ,  A61K31/397 ,  A61P3/06

摘要： The present invention relates to a pharmaceutical composition and a therapeutic combination comprising obicetrapib and ezetimibe, which may be used in the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia and wherein said subjects are partially or completely intolerant to statins.

公开(公告)号：US11970482B2

公开(公告)日：2024-04-30

申请号：US16960681

申请日：2019-01-08

申请人： Ligand Pharmaceuticals Incorporated

发明人： Lin Zhi

IPC分类号： C07D405/14 ,  C07D239/42 ,  C07D405/06 ,  A61K31/397 ,  A61K45/06

CPC分类号： C07D405/14 ,  C07D239/42 ,  C07D405/06 ,  A61K31/397 ,  A61K45/06

摘要： Disclosed herein are acetal and cyclic acetal compounds, compositions, their preparation, and their uses. Some embodiments relate to their use as liver-targeting compounds.

公开(公告)号：US20240066038A1

公开(公告)日：2024-02-29

申请号：US18260423

申请日：2022-01-06

申请人： MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

发明人： Guojun Bu ,  Yonghe Li ,  Thomas Caulfield

IPC分类号： A61K31/55 ,  A61K31/397 ,  A61K31/40 ,  A61K31/438 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P25/28

CPC分类号： A61K31/55 ,  A61K31/397 ,  A61K31/40 ,  A61K31/438 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P25/28

摘要： Provided herein are methods of treating a central nervous system injury by administering a Wnt modulator to a subject suffering therefrom.

公开(公告)号：US20240000748A1

公开(公告)日：2024-01-04

申请号：US18253025

申请日：2021-11-17

申请人： Anebulo Pharmaceuticals, Inc.

发明人： Joseph Fenton LAWLER ,  Daniel Pawel SCHNEEBERGER

IPC分类号： A61K31/397 ,  A61P25/30

CPC分类号： A61K31/397 ,  A61P25/30

摘要： Described herein are uses of the CB1 inhibitors (e.g., antagonists, neutral antagonists, inverse agonists) and various methods of using and administering a CB1 inhibitor to a patient, especially patients showing symptoms of drug overdose or suspected of a drug overdose. Further described herein are uses wherein the CB1 inhibitor is ANEB-001. Further described herein are treatments with a CB1 inhibitor for THC or synthetic cannabinoid overdose.

公开(公告)号：US20230312750A1

公开(公告)日：2023-10-05

申请号：US17776295

申请日：2020-11-18

申请人： AD Pharmaceuticals Co., Ltd.

发明人： Baiyong LI ,  Yu XIA ,  Zhongmin WANG ,  Xiaoping JIN

IPC分类号： C07K16/40 ,  A61K39/395 ,  A61K31/366 ,  A61K31/22 ,  A61K31/405 ,  A61K31/40 ,  A61K31/505 ,  A61K31/47 ,  A61K31/397 ,  A61P3/06

CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K31/366 ,  A61K31/22 ,  A61K31/405 ,  A61K31/40 ,  A61K31/505 ,  A61K31/47 ,  A61K31/397 ,  A61P3/06

摘要： Provided are an anti-PCSK9 antibody and a use thereof preferably for the treatment of hypercholesterolemia.